Astellas Pharma US, Inc.
NEWS
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Roxadustat was non-inferior to Aranesp in hemoglobin levels during the first 24 weeks of treatment, which was the trial’s primary endpoint.
Under terms of the agreement, Astellas will make an upfront cash payment of $80 million to CytomX.
Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.
Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer.
It is planned to go into operation in 2021, and is expected to create more than 200 new jobs in Lee County, North Carolina.
Two months after Pfizer and Astellas’ Xtandi won regulatory approval for a new indication in prostate cancer, the companies have released positive new data in another type of prostate cancer.
Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, said the partnership with Astellas builds upon and extends an existing collaboration focused on gene editing of iPSC cells.
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
JOBS
IN THE PRESS